36 results on '"Delforge, Michel"'
Search Results
2. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis.
3. Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders
4. Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 study.
5. Velocities of Naturally Occurring Myocardial Shear Waves Increase With Age and in Cardiac Amyloidosis.
6. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
7. Concise review ‐ Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
8. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
9. P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma.
10. P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial.
11. OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa.
12. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
13. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
14. Aprotinin Reduces Cardiac Troponin I Release and Inhibits Apoptosis of Polymorphonuclear Cells During Off-Pump Coronary Artery Bypass Surgery.
15. Amifostine does not preferentially stimulate the growth of residual polyclonal progenitor cells in myelodysplastic syndromes
16. P-162: Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients.
17. OAB-023: Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2.
18. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
19. Corrigendum to “Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders” [Clinica Chimica Acta 410 (2009) 54–58]
20. Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant.
21. Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA.
22. Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA.
23. The Relation of Ejection Fraction and Global Longitudinal Strain in Amyloidosis: Implications for Differential Diagnosis.
24. Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM).
25. Low-pass Sequencing of Plasma Cell DNA and of ccfDNA for the Detection of Copy Number Aberrations and Early Response Monitoring in Multiple Myeloma.
26. Effect of Treatment with Lenalidomide Plus Low-Dose Dexamethasone Until Progression on Health-Related Quality of Life Over Time in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.
27. Treatment With Doxycycline for Severe Bortezomib-Associated Blepharitis.
28. SP-028 APPROACH IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA.
29. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
30. Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasia.
31. Pain during bone marrow aspiration: prevalence and prevention
32. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
33. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
34. Monoclonal Gammopathy of Undetermined Significance: Significant Beyond Hematology.
35. The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients
36. Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.